
Delcath Systems (DCTH) Stock Forecast & Price Target
Delcath Systems (DCTH) Analyst Ratings
Bulls say
Delcath Systems is poised for strong growth driven by its selective approach to site quality, which could support volume growth per site and improve its financials. The company reported strong financials for the second quarter of 2026, with an increase in revenue and net income, and raised its 2026 revenue guidance based on the strength of its sales performance, adding two more centers to its active treatment centers. With a focus on key drivers of growth, including high-volume academic institutions and recurring referrals, as well as improved commercial execution, Delcath Systems is on track for continued success in the future.
Bears say
Delcath Systems is reporting better than expected gross margins due to operational efficiencies and has adjusted their R&D and SG&A expenses for the remainder of 2026 as a result. The company has 13 active screening sites for its Phase 2 randomized controlled trial (RCT) in liver-dominant metastatic colorectal cancer, with expected interim results in late 2027, and 6 active screening sites for its RCT in liver-dominant metastatic breast cancer. The first patients in the breast cancer trial have recently been dosed.
This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.
Delcath Systems (DCTH) Analyst Forecast & Price Prediction
Start investing in Delcath Systems (DCTH)
Order type
Buy in
Order amount
Est. shares
0 shares